FTC sues Watson and Par over AndroGel deal
US generic drugmaker Watson Pharmaceuticals says that the Federal Trade Commission and the State of California have filed a lawsuit in the US District Court for the Central District of California alleging that its 2006 patent lawsuit settlement with Belgian pharmaceutical firm Solvay for AndroGel 1% (testosterone gel) CIII is unlawful.
In 2003, Watson submitted an Abbreviated New Drug Application seeking approval to market a generic version of Solvay's testosterone replacement product. The Belgian firm initiated litigation alleging that Watson's product infringed its patent.
Under the terms of a 2006 settlement deal, Solvay granted Watson a non-exclusive license to the US patents covering AndroGel and in return, the local firm agreed not to commence marketing its generic equivalent product until August 31, 2015 or until another generic product enters the US market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze